ERBB2 and cancer: In a report studying the HER2 somatic mutations in human breast cancers, it was found that the prevalence was not high in primary tumors with an overall rate of 2.24% (2.31% for HER2-positive cancers and 2.07% for HER2-negative cancers) (41).